AI Automated Translation.

Font Size

Share

Boryeong and Celltrion Pharmaceuticals to co-sell diabetes treatment with annual prescription value of 51.7 billion won

Boryeong and Celltrion Pharmaceuticals to co-sell diabetes treatment with annual prescription value of 51.7 billion won

Six oral treatments including Nesina and Actos… Domestic sales and marketing cooperation starting January next year
Secures original product lines in DPP-4 inhibitor and TZD classes, coinciding with the launch of Boryeong Pharma Solutions

Jung Woong-je, head of Boryeong's sales division (left), and Yoo Young-ho, CEO of Celltrion Pharmaceuticals, pose for a commemorative photo at the "Nesina and Actos Joint Promotion and Exclusive Sales and Distribution Contract Signing Ceremony" held on the 16th at Celltrion Pharmaceuticals' Gwacheon office. /Photo=Boryeong
Jung Woong-je, head of Boryeong's sales division (left), and Yoo Young-ho, CEO of Celltrion Pharmaceuticals, pose for a commemorative photo at the "Nesina and Actos Joint Promotion and Exclusive Sales and Distribution Contract Signing Ceremony" held on the 16th at Celltrion Pharmaceuticals' Gwacheon office. /Photo=Boryeong

Boryeong and Celltrion Pharmaceuticals are set to co-sell six diabetes treatments that recorded a domestic prescription value of 51.7 billion won last year. Boryeong Pharma Solutions, a sales and marketing subsidiary of Boryeong launching in January next year, will expand its product lineup by adding original pharmaceuticals to its existing diabetes treatments.

Boryeong and Celltrion Pharmaceuticals announced on the 16th that they have signed a joint sales contract for the "Nesina" and "Actos" product lines for type 2 diabetes treatment. The two companies will jointly conduct domestic sales and marketing activities for a total of six oral diabetes treatments starting in January next year.

The products subject to joint sales include Nesina tablets (alogliptin), Nesina Met tablets (alogliptin and metformin), Nesina Met extended-release tablets (alogliptin and metformin), Actos tablets (pioglitazone), Actos Met tablets (pioglitazone and metformin), and Nesina Act tablets (alogliptin and pioglitazone).

Nesina is an original pharmaceutical containing the ingredient alogliptin, approved by the U.S. Food and Drug Administration (FDA) in 2013, belonging to the DPP-4 inhibitor class of hypoglycemic agents. Actos is a TZD-class treatment that improves insulin resistance, receiving FDA approval in 1999. Nesina Act, a combination drug combining the two ingredients, received FDA approval in 2013.

The Nesina and Actos product lines are pharmaceuticals acquired by Celltrion from Takeda in 2020. According to pharmaceutical market research firm Ubist, the domestic prescription value last year was 51.7 billion won. The lineup consists of various products ranging from single-agent to combination drugs, allowing prescriptions based on the patient's condition and stage of treatment.

With this contract, Boryeong's diabetes treatment product lineup will also expand. Boryeong currently sells "Trubirdy," a combination drug of dapagliflozin and pioglitazone, and "Trudapa," a single-agent dapagliflozin product. By adding original products in the DPP-4 inhibitor and TZD classes, the company will broaden the range of treatment options.

In particular, Boryeong Pharma Solutions, launching in January next year, plans to strengthen sales and marketing for diabetes treatments based on this joint sales product lineup. Boryeong aims to expand its position in the domestic market by combining its existing sales foundation with the product competitiveness of Celltrion Pharmaceuticals.

Yoo Young-ho, CEO of Celltrion Pharmaceuticals, said, "We have come together to cooperate based on the experience both companies have accumulated in the domestic diabetes treatment market." He added, "Together with Boryeong, we will faithfully convey information about the Nesina and Actos product lines to medical practice sites, contributing to effective treatment and improved quality of life for type 2 diabetes patients."

Jung Woong-je, Vice President of Boryeong who is set to serve as CEO of Boryeong Pharma Solutions, stated, "By introducing Celltrion Pharmaceuticals' clinically validated diabetes treatments Nesina and Actos, we have further strengthened Boryeong's diabetes treatment portfolio." He added, "Building on the sales foundation we have established in the diabetes treatment field over time, we will expand our position in the market even further."

He continued, "Based on the sales and marketing expertise of Boryeong Pharma Solutions, we will effectively convey the value of the products to medical practice sites while creating a new turning point for product growth."

"This article was translated using AI and may differ slightly from the original."